- Home
- ATLC vs NTLA Comparison
ATLC vs NTLA Comparison
Compare ATLC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- NTLA
- Stock Information
- Founded
- ATLC 1996
- NTLA 2014
- Country
- ATLC United States
- NTLA United States
- Employees
- ATLC N/A
- NTLA N/A
- Industry
- ATLC Finance: Consumer Services
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATLC Finance
- NTLA Health Care
- Exchange
- ATLC Nasdaq
- NTLA Nasdaq
- Market Cap
- ATLC 732.1M
- NTLA 710.1M
- IPO Year
- ATLC 1999
- NTLA 2016
- Fundamental
- Price
- ATLC $48.69
- NTLA $7.16
- Analyst Decision
- ATLC Strong Buy
- NTLA Buy
- Analyst Count
- ATLC 5
- NTLA 20
- Target Price
- ATLC $62.00
- NTLA $38.40
- AVG Volume (30 Days)
- ATLC 47.2K
- NTLA 5.1M
- Earning Date
- ATLC 05-08-2025
- NTLA 05-08-2025
- Dividend Yield
- ATLC N/A
- NTLA N/A
- EPS Growth
- ATLC 21.75
- NTLA N/A
- EPS
- ATLC 5.17
- NTLA N/A
- Revenue
- ATLC $424,877,000.00
- NTLA $45,569,000.00
- Revenue This Year
- ATLC $270.55
- NTLA N/A
- Revenue Next Year
- ATLC $11.94
- NTLA N/A
- P/E Ratio
- ATLC $9.40
- NTLA N/A
- Revenue Growth
- ATLC 17.71
- NTLA N/A
- 52 Week Low
- ATLC $25.14
- NTLA $5.90
- 52 Week High
- ATLC $64.70
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- ATLC 40.03
- NTLA 40.89
- Support Level
- ATLC $48.36
- NTLA $6.83
- Resistance Level
- ATLC $49.80
- NTLA $9.79
- Average True Range (ATR)
- ATLC 1.86
- NTLA 0.60
- MACD
- ATLC -0.48
- NTLA -0.21
- Stochastic Oscillator
- ATLC 20.71
- NTLA 11.17
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.